| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8232624 | International Journal of Radiation Oncology*Biology*Physics | 2010 | 7 Pages |
Abstract
The dose-dense regimen of TMZ administered in a 1-week on/1-week off schedule resulted in acceptable nonhematologic toxicity. Compared with data from the European Organization for Research and Treatment of Cancer/National Cancer Institute of Canada trial 26981-22981/CE.3, patients with an unmethylated MGMT gene promoter appeared not to benefit from intensifying the TMZ schedule regarding the median progression-free survival and overall survival. In contrast, data are promising for patients with a methylated MGMT promoter.
Related Topics
Physical Sciences and Engineering
Physics and Astronomy
Radiation
Authors
Markus M.D., Christian M.D., Dorothee M.D., Ulrich M.D., Thierry M.Sc., Oliver M.D., Richard M.D., Michael M.D., Marcos M.D., Andreas M.D., Michael M.D., Wolfgang M.D.,